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Abstract 
Background: Bacteria treated with different classes of antibiotics exhibit changes in susceptibility to successive 
antibiotic treatments. This study was designed to evaluate the influence of sequential antibiotic treatments on the 
development of antibiotic resistance in Klebsiella pneumoniae associated with β-lactamase and efflux pump activities.
Methods: The antibiotic susceptibility, β-lactamase activity, and efflux activity were determined in K. pneumoniae 
grown at 37 °C by adding initial (0 h) and second antibiotics (8 or 12 h). Treatments include control (CON; no first and 
second antibiotic addition), no initial antibiotic addition followed by 1 MIC ciprofloxacin addition (CON-CIP), no initial 
antibiotic addition followed by 1 MIC meropenem addition (CON-MER), initial 1/4 MIC ciprofloxacin addition followed 
by no antibiotic addition (1/4CIP-CON), initial 1/4 MIC ciprofloxacin addition followed by 1 MIC ciprofloxacin addition 
(1/4CIP-CIP), and initial 1/4 MIC ciprofloxacin addition followed by 1 MIC meropenem addition (1/4CIP-MER).
Results: Compared to the CON, the initial addition of 1/4 MIC ciprofloxacin inhibited the growth of K. pneumoniae 
throughout the incubation period. The ciprofloxacin treatments (CON-CIP and 1/4CIP-CIP) showed significant reduc-
tion in the number of K. pneumoniae cells compared to meropenem (CON-MER and 1/4CIP-MER). The 1/4CIP-CIP 
achieved a further 1 log reduction of K. pneumoniae, when compared to the 1/4CIP-CON and 1/CIP-MER. The increase 
in sensitivity of K. pneumoniae to cefotaxime, kanamycin, levofloxacin, nalidixic acid was observed for CON-CIP. Notice-
able cross-resistance pattern was observed at the 1/4CIP-CIP, showing the increased resistance of K. pneumoniae to 
chloramphenicol, ciprofloxacin, kanamycin, levofloxacin, nalidixic acid norfloxacin, sulphamethoxazole/trimethoprim, 
and tetracycline. The levels of β-lactamase activities were estimated to be 8.4 μmol/min/ml for CON, 7.7 μmol/min/
ml for 1/4CIP-CON and as low as 2.9 μmol/min/ml for CON-CIP. Compared to the absence of phenylalanine-arginine-
β-naphthylamide (PAβN), the fluorescence intensity of EtBr was increased in K. pneumoniae cells treated at the CON, 
CON-CIP, and CON-MER in the presence of PAβN. However, the efflux pump activity remained in K. pneumoniae cells 
treated at the 1/CIP, 1/CIP–CIP, and 1/CIP-MER in the presence of PAβN.
Conclusion: The results suggest that the pre-exposed antibiotic history, treatment order, and concentrations influ-
enced the development of multiple antibiotic resistant associated with β-lactamase and efflux pump activities. This 
study highlights the importance of antibiotic treatment conditions, which would be taken into consideration when 
new antibiotic strategy is designed to prevent antibiotic resistance.
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Background
The overuse, underuse, and misuse of antibiotics have 
become major causes of the development of antibiotic 
resistance in bacteria [1]. The emergence and spread of 
antibiotic-resistant bacteria has been a growing concern 
over the last decade, which can lead to serious clinical 
and public health problems. Klebsiella pneumoniae, an 
opportunistic pathogen, is mainly responsible for noso-
comial infections with high morbidity and mortality [2]. 
Recently, the rapid emergence of extended-spectrum 
β-lactamase (ESBL) producing K. pneumoniae has sig-
nificantly increased the risk of developing serious noso-
comial and community-acquired infections worldwide 
[3, 4]. Furthermore, multidrug-resistant K. pneumoniae 
strains can cause treatment failure with current antibiotic 
therapy [2].
The proposed resistance mechanisms of K. pneu-
moniae against different classes of antibiotics include 
release of antibiotic-inactivating enzymes, modification 
of antibiotic target sites, change in membrane perme-
ability, activation of efflux pump systems, and alteration 
of metabolic pathways [2, 5]. Among these mechanisms, 
the enzymatic degradation and efflux pump systems 
play an important role in the development of multidrug 
resistance in K. pneumoniae [6]. K. pneumoniae strains 
produce enzymes, including extended-spectrum 
β-lactamases, metallo-β-lactamases, oxacillinases, and 
carbapenemases, that can degrade β-lactam antibiotics. 
The efflux pumps, belonging to the resistance-nodula-
tion-division (RND) family, can extrude amphiphilic and 
charged antibiotics such as β-lactams, fluoroquinolones, 
and aminoglycosides [2].
The sequential and combination antibiotic therapies 
have currently been used to reduce not only the evolu-
tion of multidrug resistant bacteria but also the levels of 
antibiotics used in the treatment of bacterial infection 
[7–9]. The decreased selection pressure occurs when 
antibiotics are treated in appropriate order, which can 
prevent the emergence and spread of multidrug resist-
ance [10]. From the practical viewpoint of antibiotic 
effectiveness, however, there is an important challeng-
ing question of whether the treatment history can cause 
potential carry-over effects on the additional antibiotic 
therapy. The pre-exposure to antibiotics influences the 
acquisition of resistance to second-line antibiotics [11]. 
The beneficial and adverse effects of current therapeutic 
approaches for treating bacterial infections are still under 
debate. Therefore, the objective of this study was to eval-
uate the impact of sequential antibiotic treatments on the 
antibiotic susceptibility and resistance mechanisms of K. 
pneumoniae in association with β-lactamase and efflux 
pump activities.
Methods
Bacterial strain and culture condition
Strain of K. pneumoniae ATCC 23357 was purchased 
from American Type Culture Collection (ATCC, Manas-
sas, VA, USA). The strain was cultured in trypticase soy 
broth (TSB; BD, Becton, Dickinson and Co., Sparks, MD, 
USA) at 37 °C for 18 h. After cultivation, the culture was 
centrifuged at 3000×g for 20 min at 4 °C. The harvested 
cells were washed twice with phosphate-buffered saline 
(PBS, pH 7.2) and diluted to 108 CFU/ml for assays.
Antibiotic susceptibility assay
The susceptibility of K. pneumoniae to ciprofloxacin and 
meropenem was evaluated according to the Clinical Lab-
oratory Standards Institute (CLSI) procedure with slight 
modification [12]. All antibiotics used in this study were 
purchased from Sigma Chemicals (St. Louis, MO, USA). 
Antibiotic stock solutions were prepared by dissolving in 
glacial acetic acid for ciprofloxacin and distilled water for 
meropenem to obtain a final concentration of 10.24 mg/
ml. The stock solutions of ciprofloxacin and meropenem 
(100 μl each) were serially (1:2) diluted to concentrations 
ranging from 2 to 0 μg/ml with TSB in 96-well flat-bot-
tomed polystyrene microtiter plates (BD Falcon, San Jose, 
CA, USA). The test strain was inoculated at 105 CFU/
ml and incubated at 37 °C for 18 h. Minimum inhibitory 
concentrations (MICs) of ciprofloxacin and meropenem 
were defined as the lowest concentration of each antibi-
otic at which no visible cell growth was observed.
Dynamic time‑kill curve analysis
Time-kill curve assay was carried out to determine the 
antibiotic activities of ciprofloxacin and meropenem 
against K. pneumoniae using a sequential treatment 
scheme as described in Table  1. The initial population 
(105 CFU/ml) of K. pneumoniae was inoculated at 37  °C 
in TSB treated with (Treatments 1, 2, and 3) and without 
antibiotic (Treatments 4, 5, and 6). After being reached an 
optical density (OD) of 0.5, the non-adapted and cipro-
floxacin-adapted K. pneumoniae cells were further treated 
with no (Treatments 1 and 4) and the increased concen-
trations of ciprofloxacin (Treatments 2 and 5) and mero-
penem (Treatments 3 and 6). The survival curves were 
measured at 600 nm at every 4 h interval throughout the 
incubation period. The cultured cells were collected for 
further analyses, including bacterial enumeration, disk 
diffusion, lactamase activity, and cartwheel tests.
Microbial analysis
The collected cells were serially diluted (1:10) with PBS 
and then plated on trypticase soy agar (TSA) using an 
Autoplate Spiral Plating System (Spiral Biotech Inc., 
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Norwood, MA, USA). The plates were incubated at 37 °C 
for 24–48  h to enumerate viable cells using a QCount 
Colony Counter (Spiral Biotech Inc.). Log reduction 
(NTRT/NCON) was calculated for each treatment as com-
pared to the control (CON). NCON and NTRT represent 
the numbers of control and treatments after incubation, 
respectively.
Disk‑diffusion assay
The antibiotic susceptibility of cultured K. pneumoniae 
was determined by the disk-diffusion test. The cultured 
cells were evenly spread-plated on TSA and then allowed 
to dry for 5 min. Antibiotic disks (Becton, Dickinson and 
Company, NJ, USA), including cefotaxime (CTX; 30 μg), 
chloramphenicol (CHL; 30 μg), ciprofloxacin (CIP; 5 μg), 
kanamycin (KAN; 30 μg), levofloxacin (LEV; 5 μg), nali-
dixic acid (NAL; 30  μg), norfloxacin (NOR; 10  μg), 
sulphamethoxazole/trimethoprim (S/T; 25  μg), and tet-
racycline (TET; 30 μg), were placed on the surface of the 
agar using sterilized forceps. After incubation at 38  °C 
for 24 h, the diameters of inhibition zone were measured 
using a metric ruler.
β‑Lactamase activity assay
The β-lactamase activity was evaluated using a nitroce-
fin hydrolysis assay [13]. The cultured cells were centri-
fuged at 3000×g for 20  min at 4  °C to collect cell-free 
supernatants. The cell-free supernatants were mixed with 
20 μl of 1.5 mM nitrocefin (Biovision, Inc., CA, USA) and 
incubated at 37 °C. The absorbance was measured every 
5 min up to 1 h at 515 nm [14].
Ethidium bromide (EtBr)‑agar cartwheel assay
The cultured K. pneumoniae cells were centrifuged at 
3000×g for 20  min at 4  °C, rinsed twice with PBS, and 
then suspended in PBS with and without efflux pump 
inhibitor (phenylalanine-arginine-β-naphthylamide; 
PAβN, 8 μg/ml) [15, 16]. The prepared cells were swabbed 
on EtBr-agar plates containing EtBr (1 μg/ml) and incu-
bated at 37  °C for 18  h. After incubation, the swabbed 
EtBr-agar plates exposed to UV light were photographed 
using a Gel-doc XR System (Bio-Rad, Hertfordshire, UK).
Statistical analysis
All analyses were conducted in duplicates for three repli-
cates. Data were analyzed by the Statistical Analysis Sys-
tem (SAS) software. The General Linear Model (GLM) 
and least significant difference (LSD) procedures were 
used to compare treatments at p < 0.05.
Results
Effect of serial antibiotic treatments on the viability 
and antibiotic susceptibility
The MIC values of ciprofloxacin and meropenem were 
0.03 and 0.06 μg/ml, respectively. The survival of K. pneu-
moniae was observed during the sequential antibiotic 
treatments (Fig.  1). The growth of K. pneumoniae was 
retarded by 1/4 MIC ciprofloxacin, showing that the non- 
and ciprofloxacin-treated K. pneumoniae cells reached 
OD of 0.5 after 8 and 12  h of incubation, respectively. 
The antibiotic effects of ciprofloxacin and meropenem on 
the growth of K. pneumoniae was noticeable in the non-
adapted cells (CON-CIP and CON-MER) compared to 
the ciprofloxacin-adapted cells (1/4CIP-CIP and 1/4CIP-
MER). The number of viable K. pneumoniae cells under 
1/4CIP-CIP was significantly reduced by 1.8 log, followed 
by CON-CIP and 1/4CIP-MER (Fig. 2). The least reduc-
tion in K. pneumoniae cells was observed at the CON-
MER. The reduction rate increased with increasing the 
concentration of CIP to 0.03 μg/ml (1/4CIP-CIP), while 
no significant reduction was observed for the 1/4CIP-
MER switched from CIP to MER at the second treat-
ment. The antibiotic resistance acquisition was evaluated 
in K. pneumoniae exposed to sequential antibiotic treat-
ments (Fig.  3). The susceptibilities of K. pneumoniae to 
different classes of antibiotics varied in the treatments. 
The 1/4CIP-CIP treatment exhibited the decreased 
susceptibility to all antibiotics with exception of CTX, 
showing small clear zones (<10 cm). The enhanced sus-
ceptibility to all antibiotics tested was observed at the 
Table 1 Sequential antibiotic treatments used in this study
CON, CIP, and MER denote no antibiotic addition, ciprofloxacin, and meropenem, respectively
Treatment Antibiotic addition (h) Abbreviation Description
0 h 8 or 12 h
1 No (0) No (8) CON No first and second antibiotic addition
2 No (0) 1 MIC CIP (8) CON-CIP No initial antibiotic addition followed by 1 MIC ciprofloxacin addition
3 No (0) 1 MIC MER (8) CON-MER No initial antibiotic addition followed by 1 MIC meropenem addition
4 1/4 MIC CIP (0) No (12) 1/4CIP-CON Initial 1/4 MIC ciprofloxacin followed by no antibiotic addition
5 1/4 MIC CIP (0) 1 MIC CIP (12) 1/4CIP-CIP Initial 1/4 MIC ciprofloxacin followed by 1 MIC ciprofloxacin addition
6 1/4 MIC CIP (0) 1 MIC MER (12) 1/4CIP-MER Initial 1/4 MIC ciprofloxacin followed by 1 MIC meropenem addition
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CON-CIP treatment, while the decreased susceptibilities 
to CIP and TET were observed at the treatments, CON-
MER, 1/4CIP-CON, and 1/4CIP-MER. The treatments, 
CON-MER and 1/4CIP-MER, showed the similar resist-
ance pattern as the CON.
Effect of sequential antibiotic treatments on β‑lactamase 
and efflux pump activities
The β-lactamase activities were measured in K. pneumo-
niae cultured at sequential antibiotic treatments (Fig. 4). 
The highest β-lactamase activity was observed for the 
CON (8.4  μmol/min/ml), followed by 1/4CIP-CON 
(7.7 μmol/min/ml) and CON-MER (6.0 μmol/min/ml).
The efflux activity of K. pneumoniae in the absence 
and presence of efflux pump inhibitor (EPI; PAβN) was 
evaluated on the EtBr-agar plates (Fig.  5). The efflux 
pump activity of K. pneumoniae was observed at all treat-
ments in the absence of PAβN, showing the decreased 
fluorescence intensity (Fig. 5a). The increased EtBr accu-
mulation was observed in the presence of PAβN at the 
CON, CON-CIP, and CON-MER, while relatively low 
EtBr accumulation was observed at the 1/4CIP-CON, 
1/4CIP-CIP, and 1/4CIP-MER (Fig. 5b). The efflux pump 
activity in K. pneumoniae cells treated at the 1/4CIP-CIP, 
1/4CIP-CIP, and 1/4CIP-MER was not reduced by the 
PAβN, suggesting that the EPI-insensitive efflux systems 
were activated in K. pneumoniae cells under sublethal 
concentration of ciprofloxacin.
Discussion
This study describes the effect of sequential antibiotic 
treatments on the development of antibiotic resistance 
in K. pneumoniae. Pathogenic bacteria exposed to dif-
ferent levels and various classes of antibiotics can exhibit 
various susceptibility to additional antibiotic treatments. 
However, few studies have been focused on the devel-
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Fig. 1 Survival of Klebsiella pneumonia exposed to sequential antibi-
otics (CON, open circle; CON-CIP, open triangle; CON-MER, open square; 
1/4CIP-CON, closed circle; 1/4CIP-CIP, closed triangle; 1/4CIP-MER, 



























Fig. 2 Reduction of Klebsiella pneumonia exposed to sequential 
antibiotics. NCON and NTRT represent the numbers of control and 
treatments after incubation, respectively. Log reduction with different 














Fig. 3 Radar plot of antibiotic resistance profiles (disk diffusion in cm) 
of Klebsiella pneumonia exposed to sequential antibiotics (CON, open 
circle; CON-CIP, open triangle; CON-MER, open square; 1/4CIP-CON, 
closed circle; 1/4CIP-CIP, closed triangle; 1/4CIP-MER, closed square). 
Antibiotic discs include chloramphenicol (CHL; 30 μg), ciprofloxa-
cin (CIP; 5 μg), cefotaxime (CTX; 30 μg), kanamycin (KAN; 30 μg), 
levofloxacin (LEV; 5 μg), nalidixic acid (NAL; 30 μg), norfloxacin (NOR; 
10 μg), sulphamethoxazole/trimethoprim (S/T; 25 μg), and tetracy-
cline (TET; 30 μg)
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antibiotic treatments [11]. Thus, this study highlights the 
pre-exposed antibiotic history as an important factor for 
the evolution of antibiotic resistance.
The CON-CIP was more effectively reduced the num-
ber of K. pneumoniae cells than the CON-MER, while 
no significant difference was observed between 1/4CIP-
CON and 1/4CIP-MER (Fig. 2). The results indicate that 
meropenem was less effective against K. pneumoniae than 
ciprofloxacin. The lack of antibacterial activity of mero-
penem might be due to its short elimination half-life [17]. 
The successive ciprofloxacin treatment (1/4CIP-CIP) 
showed strong antibacterial activity against K. pneumo-
niae (Fig.  2). However, the cells exposed to 1/4CIP-CIP 
treatment induced were significantly resistant to different 
classes of antibiotics such as CHL, CIP, LEV, NAL, and 
S/T, known as cross-resistance induction (Fig.  3). This 
suggests that the sequential single-antibiotic therapy at 
different levels can lead to the emergence of antibiotic 
resistant bacteria due to the phenotypic adaptation [18]. 
Previous studies have reported that antibiotic mono-
therapy and combination therapy are the main causes 
of narrow- and broad-spectrum resistance, respectively 
[9]. The concentration of ciprofloxacin treated after the 
initial CIP exposure might be insufficient to suppress the 
development of antibiotic resistance [19]. The sequential 
antibiotic treatment, specifically 1/4CIP-CIP, can possi-
bly cause a change in antibiotic resistance. This might be 
attributed to the mode of action of antibiotics, including 
time- and concentration-dependent activities. The time-
dependent antibiotics include β-lactams and carbapen-
ems, characterized by slow antibiotic activity according 
to exposure time above MIC [20, 21]. Ciprofloxacin is 
referred to as concentration-dependent antibiotic, show-
ing antibiotic activity at high concentration [22]. Due 
to the bacterial adaptation, the sequential treatment of 
homogeneous antibiotic can reduce the susceptibility to 
same and different classes of antibiotics [19, 23]. Homo-
geneous treatment increases bacterial fitness and selec-
tion pressure, resulting in the development of antibiotic 
resistance [24, 25].
The strain of K. pneumoniae used in this study was 
intrinsically resistant to ampicillin (MIC  >  256  μg/ml), 
piperazine (MIC > 16 μg/ml), cephalotin (MIC > 32 μg/
ml), and cefoxitin (MIC  >  16  μg/ml), resulted from the 
production of β-lactamases [26]. No significant change 
in β-lactamase activities was observed for 1/4CIP-CON 






























Fig. 4 Hydrolyzing activity of the β-lactamases produced from 
Klebsiella pneumonia exposed to sequential antibiotics (CON, CON-
CIP, CON-MER, 1/4CIP-CON, 1/4CIP-CIP, and 1/4CIP-MER). Means with 
different letters (a–d) are significantly different at p < 0.05
Fig. 5 Accumulation and efflux activity of Klebsiella pneumonia on EtBr agar plates containing without (a) and with (b) efflux pump inhibitor 
(PAβN). (1 CON; 2 CON-CIP; 3 CON-MER; 4, 1/4CIP-CON; 5 1/4CIP-CIP; 6 1/4CIP-MER)
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activities were significantly decreased at the CON-
CIP, CON-MER, 1/4CIP-CIP, and 1/4CIP-MER. The 
decrease in lactamase activity suggest that relatively 
fewer viable cells were observed at the treatments com-
pared to the CON and the antibiotics used may act as a 
lactamase inhibitor [27]. K. pneumoniae cells exposed to 
CON-CIP showed the increased susceptibility to CTX 
(Fig. 3), which corresponds to the significant reduction in 
β-lactamase activity treated at CON-CIP (2.9 μmol/min/
ml) (Fig.  4). The mechanisms of resistance to β-lactam 
antibiotics include not only the increase in β-lactamases-
mediated hydrolysis but also the decrease in uptake 
through porin channels and the increase in efflux pump 
activity [6, 28]. The alteration in porin channel results 
in the decrease in membrane permeability to antibiot-
ics such as β-lactams and quinolones, but not amino-
glycosides that can enter the outer membrane through 
lipopolysaccharide (LPS) uptake system [19]. The results 
explain that the susceptibilities of K. pneumoniae cells 
grown at all treatments to KAN were constant regardless 
of the levels of β-lactamase activities (Fig.  3). Carbap-
enems such as imipenem and meropenem are stable to 
β-lactamases that can hydrolyze β-lactams [28–30]. The 
production of β-lactamases can contribute to the hydrol-
ysis, resulting in the enhanced resistance to β-lactam 
antibiotics that cannot reach penicillin binding protein 
(PBP) [26]. This is in good agreement with the result of 
antibiotic susceptibility that K. pneumoniae possesses 
high intrinsic resistance to ampicillin (MIC > 256 μg/ml).
The efflux pump systems competitively expel sub-
strates, which plays an important role in the develop-
ment of multidrug resistance [2]. The specific substrates 
for efflux pumps in K. pneumoniae treated at 1/4CIP-CIP 
and 1/4CIP-CIP may include CHL, TET, NOR, NAL, and 
LEV, corresponding the enhanced multiple antibiotic 
resistance in disk-diffusion assay in Fig. 3. The intracellu-
lar concentrations of antibiotics substrates in bacteria are 
directly reduced by active efflux pump systems, leading 
to the decreased antibiotic susceptibility [31]. In other 
words, the inhibition of efflux pumps can restore anti-
biotic susceptibility in resistant bacteria, suggesting the 
EPI can be a possible control method against antibiotic-
resistant bacteria [32–34]. The activation of efflux pumps 
is associated with the fast-acting antibiotic mechanism at 
the early stage of antibiotic resistance development [19]. 
The substrate-dependent efflux pump systems may con-
tribute to cross-resistance to different classes of antibiot-
ics [35].
Conclusions
This study highlights the influence of using sequen-
tial antibiotic treatment on the development of anti-
biotic resistance in K. pneumoniae. The difference in 
antibiotic activity against K. pneumoniae might be due 
to the time- and concentration-dependent modes of 
action of meropenem and ciprofloxacin, respectively. 
The antibiotic resistance mechanisms can occur within 
a short time in association with lactamase produc-
tion, membrane permeability, and efflux pump activ-
ity. The efflux pump activities in K. pneumoniae cells 
treated at 1/4CIP-CON, 1/4CIP-CIP, and 1/4CIP-MER 
were still observed in the presence of PAβN, indicat-
ing that various types of substrate-dependent efflux 
pumps exist to reduce the intracellular concentrations 
of antibiotics. The induced efflux pump activity are 
responsible for the increased antibiotic resistance in K. 
pneumoniae. The most significant finding in this study 
was that K. pneumoniae treated with sequential anti-
biotics, specifically 1/4CIP-CIP, showed reduced sus-
ceptibility towards CHL, NOR, NAL, and LEV, leading 
to the multiple antibiotic resistance. Therefore, antibi-
otic therapies should take into account the history of 
pre-exposed antibiotics to prevent the development 
of antibiotic resistance. Further studies are needed to 
assess the risk of antibiotic resistance in sequential and 
combination antibiotic therapies, which is essential 
to design an effective strategy for controlling multiple 
antibiotic resistant bacteria.
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